The system consists of an implantable pulse generator, the Omnia programmer, and a remote for patient control. The pulse generator battery lasts ten years regardless of stimulation profile used by the patient. The device also has conditional full body MRI approval.
“Following a successful launch in the United States late last year, we are excited to now have approval for the Senza Omnia SCS system in Europe,” said D. Keith Grossman, CEO of Nevro, in a statement. “This next-generation SCS system has been developed in close consultation with customers and is designed to provide a comprehensive solution to manage chronic pain. Omnia’s versatility means that patients now have access to a full range of SCS solutions and physicians can have the peace of mind that when they implant the system, they will have the capabilities needed to achieve the best possible outcomes for their patients.”
Product Page: Senza Omnia
Flashback: Senza Omnia Stimulator for Chronic Pain, with Widest Frequency Range, FDA Approved